There were 1,443 press releases posted in the last 24 hours and 358,179 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image